Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Weekly News Recap #Phispers
1. Ly3502970
1. 2212020-52-3
2. Ly3502970
3. Chembl4446782
4. Ly-3502970
5. 3-[(1s,2s)-1-[5-[(4s)-2,2-dimethyloxan-4-yl]-2-[(4s)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4h-1,2,4-oxadiazol-5-one
6. 3-[(1s,2s)-1-(5-[(4s)-2,2-dimethyloxan-4-yl]-2-{(4s)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1h-indazol-5-yl)-2-oxo-2,3-dihydro-1h-imidazol-1-yl]-4-methyl-2,4,6,7-tetrahydro-5h-pyrazolo[4,3-c]pyridine-5-carbonyl}-1h-indol-1-yl)-2-methylcyclopropyl]-1,2,4-oxadiazol-5(4h)-one
7. V6g
8. Orforglipron [inn]
9. Orforglipron [usan]
10. Ly3502970 (orforglipron)
11. Owl833
12. Schembl21175277
13. Gtpl12175
14. 7zw40d021m
15. Ex-a7751
16. Bdbm50514045
17. Akos040733262
18. Glp-1 Receptor Agonist 1;orforglipron
19. Ms-31635
20. Hy-112185
21. Cs-0043632
22. 1,2,4-oxadiazol-5(2h)-one, 3-[(1s,2s)-1-[2-[[(4s)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1h-indazol-5-yl)-2,3-dihydro-2-oxo-1h-imidazol-1-yl]-2,4,6,7-tetrahydro-4-methyl-5h-pyrazolo[4,3-c]pyridin-5-yl]carbonyl]-5-[(4s)-tetrahydro-2,2-dimethyl-2h-pyran-4-yl]-1h-indol-1-yl]-2-methylcyclopropyl]-
23. 3-[(1s,2s)-1-({2-(4-fluoro-3,5-dimethylphenyl)-3-({3-[3-(4-fluoro-1-methyl-1h-indazol-5-yl)-2-oxo-2,3-dihydro-1h-imidazol-1-yl]-4-methyl-2,4,6,7-tetrahydro-5h-pyrazolo[4,3-c]pyridin-5-yl}carbonyl)-5-[(4s)-2,2-dimethyloxan-4-yl]-1h-indol-1-yl}-2-methylcyclopropyl]-5-oxo-1,2,4-oxadiazol-4(5h)-ide
Molecular Weight | 883.0 g/mol |
---|---|
Molecular Formula | C48H48F2N10O5 |
XLogP3 | 6.8 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 10 |
Rotatable Bond Count | 7 |
Exact Mass | g/mol |
Monoisotopic Mass | g/mol |
Topological Polar Surface Area | 144 |
Heavy Atom Count | 65 |
Formal Charge | 0 |
Complexity | 1950 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Fujian Genohope Biotech is a leading provider of high-potency peptide APIs, offering GMP quality and worldwide delivery.
China's leading API and intermediate manufacturer, offering CMO/CDMO services and exports to 70+ countries, enhancing global health.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 41815
Submission : 2025-04-27
Status : Active
Type : II
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 41884
Submission : 2025-05-29
Status : Active
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 41815
Submission : 2025-04-27
Status : Active
Type : II
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 41884
Submission : 2025-05-29
Status : Active
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 42012
Submission : 2025-05-26
Status : Active
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
NDC Package Code : 63419-0603
Start Marketing Date : 2024-12-11
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
NDC Package Code : 84502-107
Start Marketing Date : 2025-06-11
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Details:
LY3502970 (orforglipron hemicalcium hydrate) is a once-daily oral nonpeptide GLP-1 receptor agonist. It is being evaluated in phase 3 clinical trials for the treatment of adults with Type 2 Diabetes.
Lead Product(s): Orforglipron Calcium Hydrate
Therapeutic Area: Endocrinology Brand Name: LY3502970
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 17, 2025
Lead Product(s) : Orforglipron Calcium Hydrate
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lilly’s Oral GLP-1 Orforglipron Shows Success in Phase 3 with Comparable Safety
Details : LY3502970 (orforglipron hemicalcium hydrate) is a once-daily oral nonpeptide GLP-1 receptor agonist. It is being evaluated in phase 3 clinical trials for the treatment of adults with Type 2 Diabetes.
Product Name : LY3502970
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 17, 2025
Details:
LY3502970 (orforglipron) is a once-daily oral nonpeptide GLP-1 receptor agonist. It is being evaluated in phase 3 clinical trials for the treatment of adults with Type 2 Diabetes.
Lead Product(s): Orforglipron Calcium Hydrate
Therapeutic Area: Endocrinology Brand Name: LY3502970
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Chugai Pharmaceutical
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 28, 2023
Lead Product(s) : Orforglipron Calcium Hydrate
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Chugai Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Eli Lilly Gets CDSCO Panel Nod to Supply Antidiabetic Drug Orforglipron
Details : LY3502970 (orforglipron) is a once-daily oral nonpeptide GLP-1 receptor agonist. It is being evaluated in phase 3 clinical trials for the treatment of adults with Type 2 Diabetes.
Product Name : LY3502970
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 28, 2023
Details:
LY3502970 (orforglipron), is first nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist being studied for chronic weight management in participants with obesity or overweight.
Lead Product(s): Orforglipron Calcium Hydrate
Therapeutic Area: Nutrition and Weight Loss Brand Name: LY3502970
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Chugai Pharmaceutical
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 23, 2023
Lead Product(s) : Orforglipron Calcium Hydrate
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Chugai Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LY3502970 (orforglipron), is first nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist being studied for chronic weight management in participants with obesity or overweight.
Product Name : LY3502970
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 23, 2023
Details:
LY3502970 (orforglipron), is first nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist being studied for chronic weight management in participants with obesity or overweight.
Lead Product(s): Orforglipron Calcium Hydrate
Therapeutic Area: Nutrition and Weight Loss Brand Name: LY3502970
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Chugai Pharmaceutical
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 20, 2023
Lead Product(s) : Orforglipron Calcium Hydrate
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Chugai Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LY3502970 (orforglipron), is first nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist being studied for chronic weight management in participants with obesity or overweight.
Product Name : LY3502970
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 20, 2023
https://www.pharmacompass.com/pipeline-prospector-blog/pipeline-prospector-april-2025-merck-kgaa-buys-springwork-for-us-3-9-bn-swiss-giants-lead-pharma-migration-to-us-soil
Market Place
Reply
11 Jul 2025
ABOUT THIS PAGE
33
PharmaCompass offers a list of Orforglipron Calcium Hydrate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Orforglipron Calcium Hydrate manufacturer or Orforglipron Calcium Hydrate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Orforglipron Calcium Hydrate manufacturer or Orforglipron Calcium Hydrate supplier.
PharmaCompass also assists you with knowing the Orforglipron Calcium Hydrate API Price utilized in the formulation of products. Orforglipron Calcium Hydrate API Price is not always fixed or binding as the Orforglipron Calcium Hydrate Price is obtained through a variety of data sources. The Orforglipron Calcium Hydrate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Orforglipron Calcium Hydrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Orforglipron Calcium Hydrate, including repackagers and relabelers. The FDA regulates Orforglipron Calcium Hydrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Orforglipron Calcium Hydrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Orforglipron Calcium Hydrate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Orforglipron Calcium Hydrate supplier is an individual or a company that provides Orforglipron Calcium Hydrate active pharmaceutical ingredient (API) or Orforglipron Calcium Hydrate finished formulations upon request. The Orforglipron Calcium Hydrate suppliers may include Orforglipron Calcium Hydrate API manufacturers, exporters, distributors and traders.
click here to find a list of Orforglipron Calcium Hydrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Orforglipron Calcium Hydrate DMF (Drug Master File) is a document detailing the whole manufacturing process of Orforglipron Calcium Hydrate active pharmaceutical ingredient (API) in detail. Different forms of Orforglipron Calcium Hydrate DMFs exist exist since differing nations have different regulations, such as Orforglipron Calcium Hydrate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Orforglipron Calcium Hydrate DMF submitted to regulatory agencies in the US is known as a USDMF. Orforglipron Calcium Hydrate USDMF includes data on Orforglipron Calcium Hydrate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Orforglipron Calcium Hydrate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Orforglipron Calcium Hydrate suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Orforglipron Calcium Hydrate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Orforglipron Calcium Hydrate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Orforglipron Calcium Hydrate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Orforglipron Calcium Hydrate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Orforglipron Calcium Hydrate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Orforglipron Calcium Hydrate suppliers with NDC on PharmaCompass.
Orforglipron Calcium Hydrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Orforglipron Calcium Hydrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Orforglipron Calcium Hydrate GMP manufacturer or Orforglipron Calcium Hydrate GMP API supplier for your needs.
A Orforglipron Calcium Hydrate CoA (Certificate of Analysis) is a formal document that attests to Orforglipron Calcium Hydrate's compliance with Orforglipron Calcium Hydrate specifications and serves as a tool for batch-level quality control.
Orforglipron Calcium Hydrate CoA mostly includes findings from lab analyses of a specific batch. For each Orforglipron Calcium Hydrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Orforglipron Calcium Hydrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Orforglipron Calcium Hydrate EP), Orforglipron Calcium Hydrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Orforglipron Calcium Hydrate USP).